Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH… Read more
Wockhardt Limited (WOCKPHARMA) - Net Assets
Latest net assets as of March 2025: ₹46.57 Billion INR
Based on the latest financial reports, Wockhardt Limited (WOCKPHARMA) has net assets worth ₹46.57 Billion INR as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹81.35 Billion) and total liabilities (₹34.78 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹46.57 Billion |
| % of Total Assets | 57.25% |
| Annual Growth Rate | 10.64% |
| 5-Year Change | 23.85% |
| 10-Year Change | 7.24% |
| Growth Volatility | 24.87 |
Wockhardt Limited - Net Assets Trend (2005–2025)
This chart illustrates how Wockhardt Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Wockhardt Limited (2005–2025)
The table below shows the annual net assets of Wockhardt Limited from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹46.57 Billion | +27.17% |
| 2024-03-31 | ₹36.62 Billion | 0.00% |
| 2023-03-31 | ₹36.62 Billion | -12.85% |
| 2022-03-31 | ₹42.02 Billion | +11.75% |
| 2021-03-31 | ₹37.60 Billion | +22.99% |
| 2020-03-31 | ₹30.57 Billion | +1.76% |
| 2019-03-31 | ₹30.05 Billion | -6.04% |
| 2018-03-31 | ₹31.98 Billion | -14.00% |
| 2017-03-31 | ₹37.19 Billion | -14.37% |
| 2016-03-31 | ₹43.43 Billion | +12.53% |
| 2015-03-31 | ₹38.59 Billion | +3.81% |
| 2014-03-31 | ₹37.18 Billion | +37.48% |
| 2013-03-31 | ₹27.04 Billion | +83.83% |
| 2012-03-31 | ₹14.71 Billion | +30.59% |
| 2011-03-31 | ₹11.26 Billion | +34.86% |
| 2010-03-31 | ₹8.35 Billion | -17.93% |
| 2009-03-31 | ₹10.18 Billion | -20.09% |
| 2008-03-31 | ₹12.74 Billion | +19.44% |
| 2007-03-31 | ₹10.66 Billion | +30.66% |
| 2006-03-31 | ₹8.16 Billion | +32.36% |
| 2005-03-31 | ₹6.17 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Wockhardt Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 188000000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹1.88 Billion | 4.32% |
| Common Stock | ₹810.00 Million | 1.86% |
| Other Comprehensive Income | ₹18.44 Billion | 42.36% |
| Other Components | ₹22.40 Billion | 51.46% |
| Total Equity | ₹43.53 Billion | 100.00% |
Wockhardt Limited Competitors by Market Cap
The table below lists competitors of Wockhardt Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WH Smith PLC
PINK:WHTPF
|
$1.05 Billion |
|
Bolsa Mexicana de Valores S.A.B. de C.V
OTCGREY:BOMXF
|
$1.05 Billion |
|
Ternium Argentina SA
BA:TXAR
|
$1.05 Billion |
|
Air Transport Services Group Inc
NASDAQ:ATSG
|
$1.05 Billion |
|
Taiji Computer Corp Ltd
SHE:002368
|
$1.05 Billion |
|
Precinct Properties New Zealand Limited
PINK:AOTUF
|
$1.05 Billion |
|
Hanwha Investment&Securities Co Ltd
KO:003530
|
$1.05 Billion |
|
Beijing VRV Software Corp Ltd
SHE:300352
|
$1.05 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Wockhardt Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 33,590,000,000 to 43,530,000,000, a change of 9,940,000,000 (29.6%).
- Net loss of 470,000,000 reduced equity.
- Share repurchases of 9,830,000,000 reduced equity.
- New share issuances of 9,830,000,000 increased equity.
- Other comprehensive income increased equity by 630,000,000.
- Other factors increased equity by 9,780,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹-470.00 Million | -1.08% |
| Share Repurchases | ₹9.83 Billion | -22.58% |
| Share Issuances | ₹9.83 Billion | +22.58% |
| Other Comprehensive Income | ₹630.00 Million | +1.45% |
| Other Changes | ₹9.78 Billion | +22.47% |
| Total Change | ₹- | 29.59% |
Book Value vs Market Value Analysis
This analysis compares Wockhardt Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.28x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 22.86x to 4.28x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | ₹51.99 | ₹1188.70 | x |
| 2006-03-31 | ₹68.82 | ₹1188.70 | x |
| 2007-03-31 | ₹89.78 | ₹1188.70 | x |
| 2008-03-31 | ₹107.24 | ₹1188.70 | x |
| 2009-03-31 | ₹85.70 | ₹1188.70 | x |
| 2010-03-31 | ₹70.34 | ₹1188.70 | x |
| 2011-03-31 | ₹94.85 | ₹1188.70 | x |
| 2012-03-31 | ₹123.26 | ₹1188.70 | x |
| 2013-03-31 | ₹243.15 | ₹1188.70 | x |
| 2014-03-31 | ₹322.54 | ₹1188.70 | x |
| 2015-03-31 | ₹333.95 | ₹1188.70 | x |
| 2016-03-31 | ₹320.95 | ₹1188.70 | x |
| 2017-03-31 | ₹301.87 | ₹1188.70 | x |
| 2018-03-31 | ₹257.94 | ₹1188.70 | x |
| 2019-03-31 | ₹241.71 | ₹1188.70 | x |
| 2020-03-31 | ₹241.30 | ₹1188.70 | x |
| 2021-03-31 | ₹281.06 | ₹1188.70 | x |
| 2022-03-31 | ₹319.26 | ₹1188.70 | x |
| 2023-03-31 | ₹232.81 | ₹1188.70 | x |
| 2024-03-31 | ₹232.86 | ₹1188.70 | x |
| 2025-03-31 | ₹277.42 | ₹1188.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Wockhardt Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.08%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.55%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.87x
- Recent ROE (-1.08%) is below the historical average (3.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 34.63% | 17.23% | 0.65x | 3.11x | ₹1.52 Billion |
| 2006 | 40.67% | 23.49% | 0.66x | 2.63x | ₹2.50 Billion |
| 2007 | 32.55% | 20.07% | 0.47x | 3.48x | ₹2.40 Billion |
| 2008 | 30.29% | 14.54% | 0.51x | 4.05x | ₹2.58 Billion |
| 2009 | -13.64% | -3.87% | 0.53x | 6.61x | ₹-2.41 Billion |
| 2010 | -119.80% | -22.23% | 0.79x | 6.85x | ₹-10.84 Billion |
| 2011 | 8.04% | 2.41% | 0.64x | 5.23x | ₹-221.24 Million |
| 2012 | 23.30% | 7.43% | 0.74x | 4.25x | ₹1.96 Billion |
| 2013 | 58.39% | 28.06% | 0.93x | 2.23x | ₹13.08 Billion |
| 2014 | 23.47% | 17.40% | 0.73x | 1.85x | ₹4.83 Billion |
| 2015 | 10.90% | 9.04% | 0.65x | 1.87x | ₹333.75 Million |
| 2016 | 6.47% | 5.63% | 0.56x | 2.05x | ₹-1.37 Billion |
| 2017 | -5.87% | -4.93% | 0.44x | 2.69x | ₹-5.29 Billion |
| 2018 | -21.33% | -15.50% | 0.48x | 2.86x | ₹-8.94 Billion |
| 2019 | -7.27% | -5.46% | 0.46x | 2.93x | ₹-4.62 Billion |
| 2020 | -2.59% | -2.43% | 0.35x | 3.06x | ₹-3.36 Billion |
| 2021 | 20.32% | 25.33% | 0.35x | 2.30x | ₹3.48 Billion |
| 2022 | -6.34% | -7.55% | 0.39x | 2.14x | ₹-6.29 Billion |
| 2023 | -16.67% | -21.04% | 0.35x | 2.29x | ₹-8.94 Billion |
| 2024 | -13.78% | -16.36% | 0.37x | 2.28x | ₹-7.99 Billion |
| 2025 | -1.08% | -1.55% | 0.37x | 1.87x | ₹-4.82 Billion |
Industry Comparison
This section compares Wockhardt Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Wockhardt Limited (WOCKPHARMA) | ₹46.57 Billion | 34.63% | 0.75x | $1.05 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |